ReviewClinical and experimental medicine2025
High-altitude pulmonary hypertension: a comprehensive review of mechanisms and management.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cognitive behavioral therapy enhances psychological and physiological outcomes in high-altitude respiratory patients.World journal of psychiatry · 2026Trial
- G Protein-Coupled Receptor in High-Altitude Diseases: Mechanistic Insights and Therapeutic Opportunities.MedComm · 2026Review
- Risk factors and outcomes of HPH in high-altitude residents via echocardiographic evaluation.BMC cardiovascular disorders · 2026Article
- Hemodynamic and Thrombotic Vulnerability in Pulmonary Arterial Hypertension at High Altitude: Multivariable Predictors of Mortality.Medicina (Kaunas, Lithuania) · 2026Article
- Therapeutic Effects of Active Compounds fromACS omega · 2026Article
- Proteomic study of high-altitude pulmonary hypertension in the Xinjiang Pamir highlanders.BMC pulmonary medicine · 2026Article
- Cellular Signalling Networks in High Altitude Pulmonary Hypertension: From Canonical Pathways to Emerging Targets.Cell proliferation · 2026Review
- One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.Veterinary sciences · 2026Review
- Hypoxic Pulmonary Hypertension: Molecular Mechanisms and Clinical Research Advances.International journal of molecular sciences · 2026Review
- Roles of the Altitude-Adapted Immune Microenvironment in Pulmonary Vascular Remodeling in High-Altitude Pulmonary Hypertension: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Pulmonary rehabilitation for pulmonary hypertension in high-altitude areas: a mixed-methods study of medical staff's perspectives.Frontiers in public health · 2026Article
- Tea consumption is associated with a reduced risk of high-altitude pulmonary hypertension among high-altitude permanent inhabitants in the Tibetan population: a case-control study.Frontiers in nutrition · 2026Article
- Cardiac Function Transition in Patients with Chronic Kidney Disease Undergoing Maintenance Hemodialysis in a High-Altitude Multi-Ethnic Region: A Comparative Study Between Yi and Non-Yi Ethnic Groups.Journal of inflammation research · 2026Article
- Post-COVID spirometric abnormalities in workers with intermittent high-altitude exposure: A cross-sectional study in Peru.PloS one · 2026Article
- DNA methylation in adaptation to high-altitude environments and pathogenesis of related diseases.Human genomics · 2025Review
- Pulmonary hypertension: etiology and anti-inflammatory treatment pathways of natural products.Frontiers in pharmacology · 2025Review
- The cardiovascular system and high-altitude exposure: from adaptation to disease. Part I.Archivos peruanos de cardiologia y cirugia cardiovascularArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
High-altitude pulmonary hypertension (HAPH) is characterized by an increase in pulmonary artery pressure due to prolonged exposure to hypoxic environment at high altitudes. The development of HAPH involves various factors such as pressure changes, inflammation, oxidative stress, gene regulation, and signal transduction. The pathophysiological mechanisms of this condition operate at molecular, cellular, and genetic levels. Diagnosis of HAPH often relies on echocardiography, cardiac catheterization, and other methods to assess pulmonary artery pressure and its impact on cardiac function. Treatment options for HAPH encompass both nondrug and drug therapies. While advancements have been made in understanding the pathological mechanisms through research on animal models and clinical trials, there are still limitations to be addressed. Future research should focus on exploring molecular targets, personalized medicine, long-term management strategies, and interdisciplinary approaches. By leveraging advanced technologies like systems biology, omics technology, big data, and artificial intelligence, a comprehensive analysis of HAPH pathogenesis can lead to the identification of new treatment targets and strategies, ultimately enhancing patient quality of life and prognosis. Furthermore, research on health monitoring and preventive measures for populations living at high altitudes should be intensified to reduce the incidence and mortality of HAPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.